Patents Examined by Kay K. Kim
  • Patent number: 5360895
    Abstract: Antibody- or antibody fragment-gold cluster conjugates are shown wherein the conjugate size can be as small as 5.0 nm. Methods and reagents are disclosed in which antibodies, Fab' or F(ab').sub.2 fragments thereof are covalently bound to a stable cluster of gold atoms. The gold clusters may contain 6, 8, 9, 11, 13, 55 or 67 gold atoms in their inner core. The clusters may also contain radioactive gold. The antibody-cluster conjugates are useful in electron microscopy applications as well as in clinical applications that include imaging, diagnosis and therapy.
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: November 1, 1994
    Assignee: Associated Universities, Inc.
    Inventors: James F. Hainfeld, Frederic R. Furuya
  • Patent number: 5358710
    Abstract: A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the administration of an immunosuppressively effective amount of a tolerogen corresponding to said foreign protein or proteins, said administration being performed prior to the administration of said protein or proteins.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: October 25, 1994
    Inventors: Alec Sehon, Pradip K. Maiti, Masaru Takata
  • Patent number: 5354554
    Abstract: Cross-linked labelled antibody conjugates are described which have at least one non-disulphide interchain bridge. The bridge may be the residue of a homo- or heterofunctional cross-linking reagent, and is located away from the antigen binding domains of the antibody. The antibody conjugates have an enhanced binding capacity and in vivo have good blood clearance and, in the presence of a tumour high tumour: blood and tumour: bone ratios. The conjugates are of use in the diagnosis and therapy of e.g. tumours and may be prepared by reaction of a cross-linking reagent with an antibody.
    Type: Grant
    Filed: January 22, 1992
    Date of Patent: October 11, 1994
    Assignee: Celltech Limited
    Inventor: Stephen K. Rhind
  • Patent number: 5354691
    Abstract: A polypeptide having amino acid sequence 172-192 of a Mycobacterium bovis BCG 64 kD polypeptide, said sequence having the formula ##STR1## as well as polypeptides derived therefrom, in the amino acid sequence of which sequence 172-179 and/or sequence 189-192 is (are) entirely or partially absent, were found to be useful as immunogens inducing resistance to auto-immune arthritis and similar auto-immune diseases.The invention relates to these polypeptides, to polypeptides showing sequential homology with these polypeptides, and to derivatives and multimers thereof. Also, microorganisms expressing the polypeptides either as such or as part of a fusion protein or as a multimer form part of the invention.Finally, the invention relates to pharmaceutical compositions, diagnostic compositions and test kits comprising a compound according to the invention.
    Type: Grant
    Filed: June 5, 1992
    Date of Patent: October 11, 1994
    Assignees: De Staat der Nederlanden Vertegenwoordigd Voor de Minister Van Welzijn, Volksgezondheid en Cultuur, Riksuniversiteit Te Utrecht, Yeda Research and Development Co., Ltd.
    Inventors: Willem Van Eden, Johannes D. A. Van Embden, Ruurd Van Der Zee, Irun R. Cohen
  • Patent number: 5352447
    Abstract: A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.
    Type: Grant
    Filed: August 10, 1992
    Date of Patent: October 4, 1994
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Virginia Johnson, Richard J. Youle
  • Patent number: 5352449
    Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.
    Type: Grant
    Filed: April 14, 1992
    Date of Patent: October 4, 1994
    Assignee: Cambridge Biotech Corporation
    Inventors: Gerald A. Beltz, Dante J. Marciani, Chung-Ho Hung, Charlotte A. Kensil
  • Patent number: 5350575
    Abstract: A recombinant DNA molecule comprising a nucleotide sequence coding for a conformational epitope of the VP2 polypeptide of IBDV. In particular, a DNA molecule comprising a sequence which substantially corresponds to the AccI-SpeI fragment, and optionally the ScaI-XhoI fragment, of the IBDV genome segment coding for the VP2 polypeptide. Synthetic peptides or polypeptides, including fused polypeptides, prepared by expression of host cells containing these DNA molecules are also disclosed, as well as compositions for stimulating an immune response against IBDV comprising at least one such synthetic peptide or polypeptides.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: September 27, 1994
    Assignee: Commonwealth Scientific and Industrial Research Organization
    Inventors: Ahmed A. Azad, Mittur N. Jagadish, Kevin J. Fahey
  • Patent number: 5350574
    Abstract: This invention provides a molecule comprising cyclosporine A or a congener of cyclosporine A which is photochemically attached to a ligand containing a reactive group. This invention also provides a composition of matter which comprises a conjugate of a compound and the aforementioned molecule wherein the compound is bound to the molecule through the reactive group. This invention further provides an antibody directed to the aforementioned composition of matter specific for cyclosporine A or congener of cyclosporine A. This invention also provides methods for detecting the presence of cyclosporine A or congener thereof, methods for detecting the concentration of cyclosporine A or congener thereof, as well as a method of monitoring levels of cyclosporine A or congener of cyclosporine A in a subject.
    Type: Grant
    Filed: May 13, 1991
    Date of Patent: September 27, 1994
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Bernard F. Erlanger, William L. Cleveland, Nicholas A. Cacalano
  • Patent number: 5344645
    Abstract: Immunogens for vaccination of mammals to prevent tick infestation and transfer of disease from ticks to host animals. The immunogens are derived from cells of pathogen-free ticks, preferably tick gut brush border cells or developing larvae cells, and provide positive responses to immunoblotting and cell mediated immune response to the host, and as well do not cause heightened cutaneous response to tick feeding.
    Type: Grant
    Filed: March 22, 1991
    Date of Patent: September 6, 1994
    Assignee: Center for Innovation and Business Development Foundation
    Inventor: Stephen K. Wikel
  • Patent number: 5342771
    Abstract: This invention provides enzyme conjugates, antigens, antibodies and diagnostic test kits used in an enzyme-linked immunosorbent assay method for determining the presence and concentration of imidazolinone compounds.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: August 30, 1994
    Assignee: American Cyanamid Company
    Inventors: Rosie B. Wong, Zareen Ahmed, Milon W. Bullock
  • Patent number: 5340749
    Abstract: A method for collecting a specimen comprising (1) subjecting a specimen and a magnetic-labeled antibody comprising a magnetic micro-particle and an antibody fixed to the micro-particle to an immunoreaction to form a reacted immunocomplex, (2) concentrating the reacted immunocomplex locally at a selected region by applying an external magnetic field, preferably a gradient magnetic field, which is produced by an electromagnet and a permanent magnetic piece so as to concentrate the magnetic flux at the selected region, and (3) collecting the immunocomplex by direct magnetic adsorption toward the magnetic pole at the region of local concentration.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: August 23, 1994
    Assignee: Nippon Telegraph and Telephone Corporation
    Inventors: Koichi Fujiwara, Hiromichi Mizutani, deceased
  • Patent number: 5338542
    Abstract: The efficacy of immunotoxins having an antibody that recognises a tumour associated antigen linked to a cytotoxin through a heterobifunctional agent of the disulphide type is improved by providing in the heterobifunctional agent a molecular grouping creating steric hindrance in relation to the disulphide link. This steric hindrance can be provided by a methyl substituted methylene group located in the heterobifunctional link adjacent to the disulphide bond.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: August 16, 1994
    Assignee: ICRF (Patents) Limited
    Inventor: Philip E. Thorpe
  • Patent number: 5334702
    Abstract: Compositions which are immunologically crossreactive with antibodies are provided, together with preparative and therapeutic methods therefor. The compositions preferably comprise a plurality of covalently bound synthetic compounds, at least one of which is individually crossreactive with at least one complementarity determining region (CDR) of the antibody. Preferred processes for preparing the immunologically crossreactive compounds comprise identifying chemical functionality such as hydroxyl groups in the CDR which participates in at least one immunological binding phenomena, determining the three-dimensional positioning of the chemical functionality, and synthesizing a compound which comprises substantially the same chemical functionality as the CDR and which has at least one conformation wherein the three-dimensional positioning of the chemical functionality is substantially identical to the three-dimensional positioning of the chemical functionality of the CDR.
    Type: Grant
    Filed: August 20, 1992
    Date of Patent: August 2, 1994
    Assignees: University of Illinois, Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Horacio U. Saragovi, Michael Kahn
  • Patent number: 5334379
    Abstract: This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor is capable of modifying immunogenicity of the carbohydrate containing antigen. The cytokine or lymphokine can be an interleukin or an interferon. The immunogenic conjugate can be used in vaccine and co-vaccine formulations.
    Type: Grant
    Filed: July 16, 1990
    Date of Patent: August 2, 1994
    Assignee: American Cyanamid Company
    Inventors: Subramonia Pillai, Ronald Eby
  • Patent number: 5331109
    Abstract: The present invention is directed to novel PCP derivatives which are synthesized for the covalent attachment to antigens or receptors (proteins or polypeptides) for the preparation of antibodies or receptors to PCP and PCP analogue metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: July 19, 1994
    Assignee: Biosite Diagnostics Incorporated
    Inventor: Kenneth F. Buechler
  • Patent number: 5324825
    Abstract: The invention pertains to terpyridine compounds having structure (I). These compounds form fluorescent lanthanide chelates with the appropriate metal ions. The fluorescent metal chelates are useful as probes in time-resolved fluorescence spectroscopy.
    Type: Grant
    Filed: October 28, 1992
    Date of Patent: June 28, 1994
    Assignee: Wallac OY
    Inventors: Jouko Kankare, Harri Takalo, Elina Hanninen, Matti Helenius, Veli-Matti Mukkala
  • Patent number: 5324512
    Abstract: The present prevention provides an effective, fast acting method of vaccination useful in suppressing gonadotropic hormone release. The vaccine utilizes LHRH conjugated at its amino terminus to a protein carrier and can be mixed with either adjuvants or detergents in order to provide an effect vaccine.
    Type: Grant
    Filed: December 26, 1990
    Date of Patent: June 28, 1994
    Assignee: The Population Council
    Inventors: Anna E. Ladd, Rosemarie B. Thau, Yun-Yen Tsong
  • Patent number: 5310687
    Abstract: A chemical moiety is disclosed which comprises a chemical, biochemical, or biological substance attached to one or more electrochemiluminescent organometallic compounds. In a preferred embodiment of the invention the substance is attached to one or more ruthenium-containing or osmium-containing luminescent organometallic compounds. Methods are disclosed for detecting low concentrations of the chemical moiety using chemiluminescent, electrochemiluminescent, and photoluminescent means. Compounds are disclosed which are useful for labeling substances of interest with ruthenium-containing and osmium-containing labels or other electrochemiluminescent labels. These labeled substances are useful in methods provided for detecting and quantifying analytes of interest in binding assays and competitive binding assays. The labeled substances are of particular use in homogeneous binding assays.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: May 10, 1994
    Assignee: Igen, Inc.
    Inventors: Allen J. Bard, George M. Whitesides
  • Patent number: 5306492
    Abstract: The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide. A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: April 26, 1994
    Assignee: American Cyanamid Company
    Inventor: Massimo Porro
  • Patent number: 5306811
    Abstract: A squamous cell carcinoma-like (SCC-like) immunoreactive antigen has been identified in human female urine. This material appears to perform the same as and quite likely have the same composition as squamous cell carcinoma associated antigen (SCC) which is a subfraction of tumor antigen 4 (TA-4). This patent also relates to the isolation, and use, of the SCC-like material.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: April 26, 1994
    Assignee: Ciba Corning Diagnostics Corp.
    Inventor: Thomas H. Duffy